CMC & Technical Operations Advisory

Independent CMC and Technical Operations leadership for complex biologics and ADCs.

First Principles CMC is an independent advisory practice working with biotechnology companies from pre-IND through registration. The work covers strategy, process, manufacturing governance, and regulatory documentation — across the full arc of development.

ben@firstprinciplescmc.com
The Practice

Clients come to First Principles CMC when a program needs CMC and Technical Operations thinking that doesn't exist in-house yet, or when a specific technical challenge requires someone who has worked through it before. The practice is independent — the analysis is shaped by the program, not by institutional process or competing priorities.

Engagements are fractional, project-based, or structured diligence. Scope is defined by what the work requires.

Focus Areas
  • Complex biologics and antibody-drug conjugates
  • IND and early clinical development
  • Late-stage development and registration
  • CDMO strategy and external manufacturing
  • Technical due diligence for investment and BD
Capabilities

Pre-IND through registration

The work is organized around the development arc. Each stage builds on the last.

Early Development
Strategy

CMC Program Architecture

Development strategy that accounts for the full arc — process development approaches, control strategy frameworks, and manufacturing partnerships designed to carry a program through IND and beyond.

Operations

CDMO Selection & Technology Transfer

Systematic CDMO evaluation and selection, technology transfer planning, and the technical oversight that keeps a program on track through the transition from lab to GMP manufacturing.

Regulatory

IND / IMPD / CTA CMC

CMC authoring, review, and regulatory strategy for global IND and IMPD filings. Documentation that reflects actual process understanding, not template language.

Clinical Development
Manufacturing

External Manufacturing Governance

Ongoing CDMO oversight across process changes, scale transitions, and supply chain complexity. Program control through the operational relationships that carry clinical supply.

Technical

Control Strategy & Comparability

Control strategy development and refinement, specification setting, and comparability assessments that support manufacturing changes and process evolution through clinical development.

Supply Chain

Clinical Supply & Distribution

Clinical supply chain design, labeling, packaging, and distribution planning. Integrated with clinical operations to support study timelines and global site requirements.

Late Stage & Registration
Process

Process Characterization & Design Space

DoE-driven characterization studies linking CPPs to CQAs, proven acceptable ranges, and design space definition. The technical foundation for late-stage regulatory submissions and post-approval flexibility.

Validation

PPQ Strategy & Process Validation

Validation strategy, PPQ protocol design and execution planning, and continued process verification frameworks aligned to FDA and EMA expectations for pre-BLA manufacturing.

Regulatory

BLA / MAA Registration Filing

CMC strategy and documentation for registration submissions. Registration batch planning, specification finalization, comparability to clinical material, and lifecycle regulatory strategy through approval.

Engagements

How the work is structured

Scope and duration are defined by what the program requires.

Fractional

Ongoing program support

Senior CMC and Technical Operations leadership on a part-time basis — covering strategy, CDMO relationships, regulatory submissions, and team development as the program evolves.

Project-based

Defined scope, specific outcome

A gap assessment before an IND, a CDMO evaluation, a process characterization strategy, a comparability assessment, or a specific regulatory package. Engagement ends when the work is done.

Technical Diligence

Asset and program evaluation

CMC and manufacturing diligence for investors, BD teams, and acquirers. Process maturity, manufacturing readiness, control strategy, regulatory standing, and the path to the next value inflection point.

Background

Benjamin Hutchins, PhD

Fifteen years in CMC and Technical Operations for complex biologics and antibody-drug conjugates, across the full range of development stages — from early process development and IND filings through first-in-human programs and late-stage CMC strategy.

At Mythic Therapeutics, built the Technical Operations function from inception as VP, growing the team to sixteen contributors across process development, manufacturing, quality, and supply chain. The program advanced its first ADC to a first-in-human clinical study. Before that, CMC leadership at Editas Medicine and nine years at ImmunoGen, where work on site-specific antibody conjugation chemistry resulted in multiple issued patents and publications in PNAS, Chemistry & Biology, and the Journal of Molecular Biology.

First Principles CMC was founded in 2025. Current advisory work includes early-stage ADC programs and clinical-stage biotech companies.

Contact ben@firstprinciplescmc.com

Available for advisory engagements. Also selectively considering executive opportunities in Technical Operations and CMC leadership.